Krista L Lanctôt, PhD

https://orcid.org/0000-0001-7024-6637
Dr. Krista Lanctôt leads a large interdisciplinary research team whose work has focused on understanding how neuropsychiatric symptoms, such a mild cognitive impairment and mood disorders, interfere with cardiac rehabilitation. The overarching theme of her work is to understand the neurobiologic basis of these symptoms as risk factors for poor response, and use this information to develop targeted interventions. For example, her work has shown links between these symptoms and inflammation, oxidative stress and lipid aberrations. Dr. Lanctôt's team uses a variety of tools including neuroimaging, lipidomics, pharmacogenetics and neuropsychiatric assessments to unravel the link between dysfunction in various cellular and molecular processes and manifestation of these symptoms in a cardiac rehabilitation population. In addition, her group has run clinical trials of dietary, pharmacologic and exercise interventions for these symptoms.

Each year tens of thousands of Canadians are diagnosed with coronary artery disease (CAD) which poses a serious risk to their health and well-being. Depression and associated symptoms of cognitive impairment are common neuropsychiatric symptoms in CAD and have a major negative impact on treatment outcomes and life expectancy. Dr. Lanctôt's work has also shown their negative impact on cardiac rehabilitation outcomes. Understanding the neurobiology of these symptoms may allow us to predict response to cardiac rehabilitation and, on a broader level, may lead to the development of novel therapies.
 
Contemp Clin Trials Commun. 2019 Sep;15:100385
Ruthirakuhan MT, Herrmann N, Gallagher D, Andreazza AC, Kiss A, Verhoeff NPLG, Black SE, Lanctôt KL
J Alzheimers Dis. 2019 Jul 16;:
Ruthirakuhan M, Herrmann N, C Andreazza A, Verhoeff NPLG, Gallagher D, Black SE, Kiss A, Lanctôt KL
Psychiatry Res. 2019 Jul 01;:
Kapoor A, Scott C, Lanctot KL, Herrmann N, Murray BJ, Thorpe KE, Lien K, Sicard M, Swartz RH
Int J Stroke. 2019 Jun 21;:1747493019847334
Lanctôt KL, Lindsay MP, Smith EE, Sahlas DJ, Foley N, Gubitz G, Austin M, Ball K, Bhogal S, Blake T, Herrmann N, Hogan D, Khan A, Longman S, King A, Leonard C, Shoniker T, Taylor T, Teed M, de Jong A, Mountain A, Casaubon LK, Dowlatshahi D, Swartz RH,...
Clin Interv Aging. 2019;14:841-848
Khan MM, Lanctôt KL, Fremes SE, Wijeysundera HC, Radhakrishnan S, Gallagher D, Gandell D, Brenkel MC, Hazan EL, Docteur NG, Herrmann N
BMC Geriatr. 2019 Jun 11;19(1):163
Mohammad D, Herrmann N, Saleem M, Swartz RH, Oh PI, Bradley J, Chan P, Ellis C, Lanctôt KL
Am J Geriatr Psychiatry. 2019 May 08;:
Herrmann N, Ruthirakuhan M, Gallagher D, Verhoeff NPLG, Kiss A, Black SE, Lanctôt KL
Eur J Clin Microbiol Infect Dis. 2019 Aug;38(8):1561-1568
Paes B, Saleem M, Kim D, Lanctôt KL, Mitchell I
J Alzheimers Dis. 2019 Apr 17;:
Eakin KA, Saleem M, Herrmann N, Cogo-Moreira H, Mielke MM, Oh PI, Haughey NJ, Venkata SLV, Lanctôt KL, Swardfager W
Pediatr Infect Dis J. 2019 Apr 10;:
Wang DY, Saleem M, Paes BA, Mitchell I, Li A, Lanctôt KL, and the CARESS Investigators

Pages


Senior Scientist, Evaluative Clinical Sciences, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute
Director, Neuropsychopharmacology Research Program, Sunnybrook Health Science Centre
Professor, Department of Psychiatry, University of Toronto
Professor, Department of Pharmacology and Toxicology, University of Toronto
Full Member, School of Graduate Studies, University of Toronto
Executive Director, MORE research group, Sunnybrook Research Institute